Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
CymaBay Therapeutics, Inc. 0I5P.L
$10.13
-$0.16 (-1.60%)
На 18:02, 12 мая 2023
Ключевые показатели
-
Marketcap
6806788.00000000
-
week52high
10.87
-
week52low
1.81
-
Revenue
-
P/E TTM
0
-
Beta
0.26159100
-
EPS
-1.32300000
-
Last Dividend
0.28500000
-
Next Earnings Date
10 мая 2023 г. в 10:59
Описание компании
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Свежие комментарии
Свежие комментарии